AlphaQuest LLC Buys 10,172 Shares of Boston Scientific Co. (NYSE:BSX)

AlphaQuest LLC lifted its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 57.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 27,958 shares of the medical equipment provider's stock after acquiring an additional 10,172 shares during the period. Boston Scientific makes up 0.3% of AlphaQuest LLC's investment portfolio, making the stock its 29th biggest position. AlphaQuest LLC's holdings in Boston Scientific were worth $2,497,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Boston Scientific by 4.4% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider's stock worth $345,205,000 after acquiring an additional 173,034 shares during the last quarter. Mechanics Bank Trust Department bought a new stake in shares of Boston Scientific during the 4th quarter worth $415,000. Highland Capital Management LLC bought a new stake in Boston Scientific in the fourth quarter worth $4,887,000. Covenant Asset Management LLC bought a new stake in Boston Scientific in the fourth quarter worth $3,405,000. Finally, Brookstone Capital Management lifted its stake in Boston Scientific by 23.7% in the fourth quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider's stock worth $9,455,000 after purchasing an additional 20,307 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on BSX. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a research note on Friday, January 10th. Stifel Nicolaus boosted their price target on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, February 6th. Raymond James boosted their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research report on Thursday, February 6th. Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. Finally, TD Cowen boosted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $108.91.

Remove Ads

Insider Transactions at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares in the company, valued at $560,103.60. This represents a 75.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP John Bradley Sorenson sold 4,119 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the transaction, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 137,302 shares of company stock worth $14,319,269. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Stock Up 0.9 %

NYSE:BSX traded up $0.90 during mid-day trading on Wednesday, hitting $96.42. 8,790,888 shares of the company's stock were exchanged, compared to its average volume of 5,772,847. The business has a fifty day moving average price of $100.80 and a 200 day moving average price of $91.52. The company has a market cap of $142.29 billion, a PE ratio of 77.14, a P/E/G ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a one year low of $65.52 and a one year high of $107.17. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Equities analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.